Dyadic International (DYAI) Competitors $1.22 -0.01 (-0.81%) As of 04/30/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock DYAI vs. TNGX, ACIU, DERM, FATE, FDMT, PBYI, TARA, IKT, PRQR, and TLSAShould you be buying Dyadic International stock or one of its competitors? The main competitors of Dyadic International include Tango Therapeutics (TNGX), AC Immune (ACIU), Journey Medical (DERM), Fate Therapeutics (FATE), 4D Molecular Therapeutics (FDMT), Puma Biotechnology (PBYI), Protara Therapeutics (TARA), Inhibikase Therapeutics (IKT), ProQR Therapeutics (PRQR), and Tiziana Life Sciences (TLSA). These companies are all part of the "pharmaceutical products" industry. Dyadic International vs. Tango Therapeutics AC Immune Journey Medical Fate Therapeutics 4D Molecular Therapeutics Puma Biotechnology Protara Therapeutics Inhibikase Therapeutics ProQR Therapeutics Tiziana Life Sciences Dyadic International (NASDAQ:DYAI) and Tango Therapeutics (NASDAQ:TNGX) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their institutional ownership, media sentiment, dividends, valuation, risk, community ranking, profitability, earnings and analyst recommendations. Is DYAI or TNGX more profitable? Dyadic International has a net margin of -188.09% compared to Tango Therapeutics' net margin of -284.42%. Tango Therapeutics' return on equity of -49.64% beat Dyadic International's return on equity.Company Net Margins Return on Equity Return on Assets Dyadic International-188.09% -149.16% -59.81% Tango Therapeutics -284.42%-49.64%-32.00% Does the media favor DYAI or TNGX? In the previous week, Tango Therapeutics had 2 more articles in the media than Dyadic International. MarketBeat recorded 4 mentions for Tango Therapeutics and 2 mentions for Dyadic International. Dyadic International's average media sentiment score of 1.44 beat Tango Therapeutics' score of 1.34 indicating that Dyadic International is being referred to more favorably in the media. Company Overall Sentiment Dyadic International Positive Tango Therapeutics Positive Which has more risk & volatility, DYAI or TNGX? Dyadic International has a beta of 0.98, meaning that its share price is 2% less volatile than the S&P 500. Comparatively, Tango Therapeutics has a beta of 1.03, meaning that its share price is 3% more volatile than the S&P 500. Does the MarketBeat Community prefer DYAI or TNGX? Dyadic International received 132 more outperform votes than Tango Therapeutics when rated by MarketBeat users. However, 74.36% of users gave Tango Therapeutics an outperform vote while only 64.40% of users gave Dyadic International an outperform vote. CompanyUnderperformOutperformDyadic InternationalOutperform Votes16164.40% Underperform Votes8935.60% Tango TherapeuticsOutperform Votes2974.36% Underperform Votes1025.64% Do analysts prefer DYAI or TNGX? Dyadic International currently has a consensus target price of $6.00, suggesting a potential upside of 391.80%. Tango Therapeutics has a consensus target price of $12.33, suggesting a potential upside of 774.70%. Given Tango Therapeutics' higher probable upside, analysts plainly believe Tango Therapeutics is more favorable than Dyadic International.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Dyadic International 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Tango Therapeutics 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do institutionals and insiders believe in DYAI or TNGX? 28.0% of Dyadic International shares are owned by institutional investors. Comparatively, 79.0% of Tango Therapeutics shares are owned by institutional investors. 28.8% of Dyadic International shares are owned by insiders. Comparatively, 6.3% of Tango Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Which has better earnings and valuation, DYAI or TNGX? Dyadic International has higher earnings, but lower revenue than Tango Therapeutics. Dyadic International is trading at a lower price-to-earnings ratio than Tango Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioDyadic International$3.50M10.50-$6.80M-$0.20-6.10Tango Therapeutics$42.07M3.62-$101.74M-$1.21-1.17 SummaryTango Therapeutics beats Dyadic International on 10 of the 17 factors compared between the two stocks. Get Dyadic International News Delivered to You Automatically Sign up to receive the latest news and ratings for DYAI and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart DYAI vs. The Competition Export to ExcelMetricDyadic InternationalBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$36.71M$3.00B$5.57B$7.82BDividend YieldN/A1.89%5.11%4.22%P/E Ratio-5.3030.4222.4218.48Price / Sales10.50498.92394.10103.91Price / CashN/A168.6838.1834.62Price / Book6.103.206.774.25Net Income-$6.80M-$72.35M$3.22B$248.23M7 Day Performance0.83%3.57%3.26%3.29%1 Month Performance-10.95%0.17%0.02%2.42%1 Year Performance-14.69%-21.21%18.01%5.54% Dyadic International Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)DYAIDyadic International2.8782 of 5 stars$1.22-0.8%$6.00+391.8%-14.7%$36.71M$3.50M-5.307Short Interest ↓Positive NewsTNGXTango Therapeutics2.3645 of 5 stars$1.38+7.0%$12.33+793.7%-81.7%$149.19M$42.07M-1.1790Upcoming EarningsNews CoveragePositive NewsACIUAC Immune2.5414 of 5 stars$1.48flat$12.00+710.8%-30.2%$148.61M$27.31M-3.22140News CoveragePositive NewsDERMJourney Medical2.6804 of 5 stars$6.33+1.3%$9.88+56.0%+101.1%$146.25M$56.13M-6.7390Short Interest ↑News CoverageFATEFate Therapeutics3.8254 of 5 stars$1.25+12.6%$5.43+334.3%-67.6%$143.26M$13.63M-0.76550Upcoming EarningsGap DownHigh Trading VolumeFDMT4D Molecular Therapeutics2.6362 of 5 stars$3.08+0.7%$26.71+767.3%-85.9%$142.61M$37,000.00-1.08120Upcoming EarningsPBYIPuma Biotechnology3.8022 of 5 stars$2.86flat$7.00+144.8%-37.3%$141.89M$230.47M5.96200Upcoming EarningsTARAProtara Therapeutics2.2195 of 5 stars$3.85-1.3%$20.40+429.9%+17.4%$141.55MN/A-1.3730Analyst ForecastIKTInhibikase Therapeutics1.5306 of 5 stars$1.89-0.5%$6.50+243.9%+53.7%$140.51M$260,000.00-0.716News CoveragePositive NewsGap DownPRQRProQR Therapeutics2.8998 of 5 stars$1.32+15.8%$9.50+619.7%-14.4%$138.88M$18.91M-4.13180Upcoming EarningsAnalyst ForecastNews CoverageTLSATiziana Life Sciences0.5129 of 5 stars$1.13+5.6%N/A+110.0%$132.04MN/A0.008Short Interest ↑News Coverage Related Companies and Tools Related Companies Tango Therapeutics Alternatives AC Immune Alternatives Journey Medical Alternatives Fate Therapeutics Alternatives 4D Molecular Therapeutics Alternatives Puma Biotechnology Alternatives Protara Therapeutics Alternatives Inhibikase Therapeutics Alternatives ProQR Therapeutics Alternatives Tiziana Life Sciences Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:DYAI) was last updated on 5/1/2025 by MarketBeat.com Staff From Our PartnersHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredIs he more powerful than Trump? Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredTrump and Buffett Are Quietly Leading America’s Gold RevivalThe “Buffett Indicator” Predicts Gold Set To Dominate for Next Decade Each time the Buffett Indicator has...Golden Portfolio | SponsoredThe next market Nvidia is positioned to dominate …Robots — built by Nvidia. Forbes says this could be " a $24 trillion opportunity for investors." Huang s...Weiss Ratings | SponsoredThis isn’t a trade war. It’s worse…Investigative Journalist Bombhsell: The Curse on the U.S Dollar Depleted retirement accounts? Meme coin inv...Stansberry Research | SponsoredThey rigged the gameThe U.S. fired the first shot with 145% tariffs. Apple relies heavily on Chinese production. Tesla needs Ch...Investors Alley | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredTrump Treasure April 19Thanks to President Trump… A $900 investment across5 specific cryptos… Could gain 12,000% so quickly tha...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Dyadic International, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Dyadic International With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy DYAI Stock Free DYAI Stock Alerts